Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer
100% of patients in the REVEAL-1 Cohort maintained at least 5% of GLP-1-induced weight loss through one year: This 5% threshold is the responder definition used as the second co-primary endpoint in the REMAIN-1 Pivotal Cohort, which evaluates a responder rate among the Revita treated participants at one year to assess the durability of the Revita procedure for weight maintenance after GLP-1 discontinuation
Low Sugar & Low FatContains just 2.4g of carbohydrates and 1.1g of fat per serving, with less than 0.8g saturated fat and minimal sugars, supporting lean muscle development
Contact our legal team today for a free case evaluation
IV drip therapy offers a fast, effective way to deliver essential fluids, vitamins, and nutrients directly into the bloodstream
Grade Language With Documentation Context Grade language should be handled with care